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In 2015 and 2018 British Journal of Pharmacology (BJP) published guidelines on experimental design 
and analysis (Curtis et al., 2015, 2018). The intention was to seek to improve the credibility of papers 
published in BJP by the simplest means possible. It is all very well for a journal to elaborate a 
framework of best practice, with lengthy explanations for each issue considered, but if authors, 
reviewers and editors fail to adopt the framework because it is too complex or nuanced then we fail 
as a journal. Consequently, unlike most other journals (Williams et al., 2018), BJP has opted for firm 
rules about a small number of issues, rather than generalised and lengthy ‘best practice advice’. We 
focused on inconsistent reporting of P values (e.g., p<0.05, p=exact value, p<different values), 
persistent and unjustified use of n=3 (or fewer), grossly unequal group sizes, and an absence of 
randomization and blinding (each of which typically occur together in many papers) that are 
particular problems in our sector and contribute to the failed replication that is undermining the 
credibility of preclinical research. We received two letters that criticise some of our guidance, and 
have written an itemised reply below. 
 
First, we make a general point. Most of the BJP guidelines are ‘conventions’, i.e., pragmatic solutions 
to practical challenges. This is particularly relevant to BJP’s requirements for group size selection. 
Setting n=5 as the minimum allowable for comparing groups by statistical analysis (the ‘n=5 rule’) is 
clearly a convention. We are not claiming n=5 is sufficient and necessary for all studies. In some 
studies, group sizes much larger than n=5 are necessary to reduce the risk of false findings, whereas 
in other studies, where the control outcome has been established repeatedly in previous published 
work, group sizes of fewer than n=5 may be sufficient. In the main, BJP publishes papers on new 
drugs, or using new transgenic animals, or evaluating variables that have not been evaluated 
previously, often a combination of all three. Novelty is the key. When work is novel, it is 
extraordinarily rare for an author to include in their Methods section a clear statement that the data 
are known to be drawn from a normally distributed population (the necessary prerequisite for the 
type of parametric analysis typically undertaken), or that they have undertaken sample size 
calculations a priori that indicate that n=X would be adequate for their design. Consequently, it 
seems that deciding on an appropriate group size is done by after-the-fact power analysis using the 
data generated by a study to justify the group size used in the study (as opposed to a priori power 
analysis) or by ‘informed judgement’ (guesswork). Moreover ‘group sizes as small as possible’ is 
normally the guiding principle. The resultant problem is that studies are often favourably treated by 
peer review if sufficiently novel, with no questioning of group size selection. This is not a problem 
that can be ignored. Most statistical software programs allow tests that run on small n (even n=2), 
but the reliability of resultant P values diminishes as group sizes become smaller (Halsey et al 2015), 
and low power is widespread and leads to higher rates of false findings (Button et al 2013). Because, 
for novel work typical of that published in BJP, a priori power calculations are normally impossible, 
our n=5 rule is therefore a convention that precludes default selection of smaller group sizes without 
adequate validation, and is designed to facilitate confidence in study outcome.  
 
However, there is a recent emergence of preclinical research where safeguards have indeed been 
put in place before the experiments were undertaken, with pre-registration of study design limiting 
unreported post hoc manipulation of analytical methods. Here is a good example of a pre-registered 
study that was modified transparently after post publication peer review of the design and proposed 
method of analysis (https://f1000research.com/articles/6-1827/v3). As a consequence, the Editors 
of BJP will consider findings of n<5 where the designs and analyses for a study have been approved a 
priori and published in a pre-registered repository (e.g., Registered Reports; https://cos.io/rr/). 
However, we must emphasize that without such a disclosure the n=5 rule will continue to apply.  
 
In addition to the comments in both letters regarding the issue discussed above we respond to 
further points raised by the authors of the two letters below. 
 
From the letter by Neuhäuser & Ruxton (2018), the first comment refers to our recommendation 
that authors design a study to have equal group sizes. The rationale for this was not made clear in 
either the 2015 or 2018 papers. Like the n=5 rule, it is a convention, and the main reasons for it are 
as follows.  
• Pre-registration of experimental design and intended methods of analysis is not yet common 
in our sector. We agree that optimally-unbalanced groups can lead to improved sensitivity 
and power when the a priori decision is made to analyse them without ANOVA and with (for 
instance) Dunnett’s tests back to a single comparator rather than all pairwise comparisons 
(Bate and Karp, 2014). However, in our experience, reviewers and editors often cannot tell 
whether experiments with unbalanced groups result from planned excellent design or 
unconsidered design and inadequate transparency, with attrition unreported and exclusions 
undeclared.  
• Some investigators do not undertake blinded and randomized studies and animals are added 
into or removed from the study after preliminary analysis. Typically, no explanation is given 
for such variation, and this is not picked up during peer review.   
• When limited numbers of rare samples are available, an equal group size design is the safest 
way to minimise the risk that if there are lost samples this will render the study unfit for 
analysis (e.g., n = 6, 6, 6 becoming n = 6, 5, 5 is preferable to n=12, 3, 3 becoming n = 12, 2, 
2).  
 
By requiring authors to declare they have designed their study to have equal group sizes, we are 
requiring authors to think about their design. Nevertheless, we note the comment and have 
determined that the author guidance should be modified to state “Exceptions to these 
guidelines will be considered (e.g., normalized data analysed parametrically without a preceding 
ANOVA arising from unbalanced experiments with low n in treatment groups) for a result where a 
full description of the intended experimental designs and analyses have been published in a date-
stamped, peer-reviewed preclinical registry together with a priori sample size calculations for each 
group involving adequate power (e.g., Registered Reports; https://cos.io/rr/).”.  
  
Neuhäuser & Ruxton (2018) go on to say “A further reason for unequal group sizes is unequal 
variances. To increase power, a larger proportion of the total sample size should be allocated to a 
group with a larger variance.” Our comments on pre-planned and published protocols (above) apply 
here, and without this we would expect studies to be designed to have equal group sizes. Otherwise, 
unequal variances means that the data are not fit for parametric statistical analysis (if 
transformation fails to homogenise variances). Also, it is difficult to fathom how one can undertake a 
randomized and blinded study and manipulate group sizes to ‘accommodate’ high variance in one 
group unless it were known a priori that one group will have a disproportionate variance, otherwise 
the accommodation would be a form of ‘P hacking’ (Head 2015).  
 
The next comment is “a general principle to “add 50% to the calculated minimum group sizes” 
(Curtis et al., 2018) is unusual and not reasonable.”  Adding 50% was proposed as helpful advice 
rather than part of our list of requirements, so it is not one of our ‘conventions’. Nevertheless, this 
general principle is likely to be unreasonable only to the (unusual) people that routinely and 
adequately power their studies a priori; systematic reviews show that, usually, most studies are 
unreasonably underpowered which inflates the incidence of false findings (e.g., Button et al 2013). 
The ‘general principle’ alluded to above is a simple way to add to the ‘n=5 rule’ to encourage 
individuals to further increase group size.  
 
Neuhäuser & Ruxton (2018) next state that “We agree that significance in classical ANOVA can be 
caused by inhomogeneity in variances. But the recommendation not to carry out post-hoc tests in 
case of a significant variance inhomogeneity is not satisfying. A better strategy would be performing 
an ANOVA designed for possible variance inhomogeneity. Several methods have been proposed for 
this.” Variance inhomogeneity (which by necessity includes large variance in some groups) may 
cause false negative findings to be reported. We are saying that when conditions do not permit 
conventional parametric analysis then an alternative must be found (we mentioned nonparametric 
tests and use of transforms).  Moreover, we have said nothing to stop authors doing what is 
suggested in the statement quoted above.   
 
Neuhäuser & Ruxton (2018) finally state “Clearly, asymptotic or approximate tests are not 
acceptable for very small samples sizes, but the minimum 5 is completely arbitrary.” This is also 
noted by Motulsky and Martin (2018) in the second letter. We have addressed this important point 
at some length in our second paragraph, above.  
 
Motulsky and Martin assert that following ANOVA it is acceptable to conduct ‘follow-up’ tests even if 
F is not significant. We very much oppose the notion of encouraging investigators to routinely 
conduct ANOVA then routinely ignore the F value. ANOVA is undertaken to examine whether a 
factor (e.g., treatment) is a significant source of variance. If it is, then a post hoc test to identify 
which treatment (which level of the factor) is the source of variance is justified. If a study is not 
blinded or randomized, and indeed in addition is made up of groups with small n, there is every 
chance that variance inhomogeneity may undermine scope for F to reach significance, and that real 
effects may be missed if post hoc tests are not undertaken. Essentially, false negatives may arise 
owing to failure to use a suitable design and not because ANOVA is intrinsically flawed. In many 
respects this exemplifies why we created the BJP requirements – the experimental design and a 
priori choice of analysis is paramount, but this is out of the scope for peer review to thoroughly 
validate. Meanwhile the choice of statistical test and its execution must follow the design. If the 
study has been designed and executed appropriately, the scope for false negative findings 
predicated by ANOVA will be minimised. However, we do agree to consider during the review 
process one exception to this rule, i.e. in the case where planned comparisons (i.e., not simply 
pairwise post hoc comparisons) have been pre-registered and peer-reviewed a priori as explained 
above; these may be undertaken in the absence of a preceding ANOVA. 
Motulsky and Michel (2018) additionally criticise the journal requirement that normalized data be 
analysed with nonparametric statistics. Our intention in the BJP guidance with this requirement was 
to stop the routine use of two-sample t tests (or equivalent tests for multiple group comparisons) 
when the control group has no variance. There are certainly occasions where the use of one-sample 
t-test is valid so long as there is evidence that the assumptions of this parametric test are not 
violated. However, as we have argued elsewhere, it is not possible to determine with any confidence 
whether, e.g., five randomly-selected samples come from a population with a normal distribution or 
not, and so a non-parametric test is preferable, avoiding the need for baseless assumptions.  
 
In conclusion, we thank the authors of the two letters for their interest in our guidance. We 
acknowledge the comments raised and agree that there are specific variations to some BJP design 
and analysis requirements that are legitimate and their inclusion should not preclude consideration 
of a manuscript by BJP. This will result in small changes to the design and analysis guidance. We will 
incorporate this into journal Instructions To Authors and capture it in the next update article 
concerning design and analysis, which will likely be published in 2021.   
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